Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study

Table 3 Statistical correlation of gene mutations with prognostic parameters

Mutated gene	Risk ratio	95 % CI	p
Partial survival (from metastatic disease onset to death or last control)
KRAS	1.257	0.628–1.739	0.4906
NRAS	1.634	1.018–2.712	0.0763
All RAS	1.345	0.968–2.158	0.0924
BRAF	3.214	1.387–7.445	0.0064
All RAS + BRAF	1.733	0.997–2.994	0.0511
PIK3CA	1.403	0.877–1.479	0.1365
Overall survival (from disease diagnosis to death or last control)
KRAS	1.219	0.983–1.512	0.0703
NRAS	1.052	0.612–1.810	0.8522
All RAS	1.108	0.932–1.316	0.2432
BRAF	4.120	2.491–6.812	<0.001
All RAS + BRAF	1.878	1.238–3.996	0.0394
PIK3CA	0.934	0.711–1.226	0.6246
Time to progression as metastatic disease (from disease diagnosis to first metastasis)
KRAS	1.077	0.843–1.677	0.1508
NRAS	1.154	0.853–1.851	0.1006
All RAS	1.277	1.025–2.371	0.0943
BRAF	2.972	1.261–6.332	0.0091
All RAS + BRAF	2.217	1.125–4.371	0.0214
PIK3CA	0.964	0.691–1.346	0.8337

ISSN: 1479-5876